Scope of US Patent 11,970,530 (Bevacizumab + Olaparib) and Full US Patent Landscape for Claiming Method-Combination, HRD/BRCA Biomarkers, and Hypertension/Progression-Free-Survival Differentials
US Patent 11,970,530 is directed to a specific US method-of-treatment combination: bevacizumab plus olaparib (or a hydrate/solvate/prodrug), at bevacizumab 10 to 20 mg/kg every 3 weeks and olaparib 300 mg twice daily, in a defined cancer and biomarker setting (ovarian/fallopian tube/primary peritoneal, breast, pancreatic cancers; HRD and specified gene mutation subsets), with a defined safety discriminator (reducing CTCAE Grade 2–4 hypertension versus bevacizumab alone) and efficacy discriminator (PFS at least ~4 months greater versus bevacizumab alone).
Below is a structured claim-scope and landscape analysis at the level used for clearance, licensing, freedom-to-operate (FTO), and Paragraph IV risk review.
What does US Patent 11,970,530 claim exactly for bevacizumab + olaparib in ovarian and related cancers?
Core independent claim (Claim 1): combination dose, cancer set, biomarkers, and comparative endpoints
Claim 1 requires all of the following elements:
-
Subject and indication set (broad cancer inclusion)
Treat a subject with one or more of:
- ovarian cancer
- fallopian tube cancer
- primary peritoneal cancer
- breast cancer
- pancreatic cancer
-
Two administered actives
- bevacizumab
- olaparib, or a hydrate/solvate/prodrug
-
Specific regimen parameters
- bevacizumab 10 to 20 mg/kg every 3 weeks
- olaparib 300 mg twice daily
-
Safety discriminator tied to comparative control
Olaparib must reduce CTCAE Grade 2, Grade 3, or Grade 4 hypertension in the subject receiving the combination versus hypertension when the subject receives bevacizumab alone.
-
Efficacy discriminator tied to comparative control
Progression-free survival (PFS) is at least ~4 months greater versus subjects receiving bevacizumab alone.
This claim is not just “combination therapy” in the abstract. It is a comparative, outcome-linked regimen claim. For infringement analysis, the “versus bevacizumab alone” comparator and the magnitude of the PFS and hypertension effects become central.
Claim 1 sub-scope additions (Claims 2 and 11–23)
Claim 2 narrows Claim 1 to ovarian cancer or breast cancer.
Claim 3–7 add HRD/HR gene mutation specificity:
- Claim 3: cancer is homologous recombination deficient (HRD)
- Claim 4: HR gene mutation selected from a long list including:
BRCA1, BRCA2, ATM, BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, RAD54L
- Claim 5: cancer cells comprise BRCA1 and/or BRCA2 and/or ATM mutation
- Claim 6: cancer cells comprise BRCA1 and/or BRCA2
- Claim 7: cancer is characterized by a tBRCA mutation (typical patent shorthand for tumor BRCA alterations, but in enforcement the exact definition used in the spec matters)
Claims 8–10 add tumor histology/epithelial subsets:
- Claim 8: advanced epithelial ovarian cancer
- Claim 9: high-grade endometrioid ovarian cancer
- Claim 10: epithelial ovarian cancer with gBRCA1 or gBRCA2 mutation
Claims 11–14 tune expected PFS improvement and prior therapy timing:
- Claim 11: PFS is about 4 to 6 months greater
- Claim 12: subject previously completed first-line platinum and/or taxane chemotherapy
- Claim 13: previously received 6 to 9 cycles of first-line platinum and/or taxane
- Claim 14: last cycle between 3 and 9 weeks prior to olaparib
Claim 15 adds bevacizumab exposure context:
- previously received at least 3 cycles of bevacizumab with the first-line platinum/taxane
Claims 16–17 further constrain bevacizumab administration:
- Claim 16: bevacizumab about 15 mg/kg every 3 weeks
- Claim 17: bevacizumab administered at no more than 22 cycles in total
Claims 18–19 add “identify the subject having hypertension”:
- Claim 18: further comprising identifying subject having hypertension
- Claim 19: hypertension is at least Grade 3 by CTCAE
Claims 20–22 scale PFS differentials by biomarker subsets:
- Claim 20: PFS at least ~12 months greater when cancer comprises BRCA mutation
- Claim 21: PFS at least ~10 months greater when HRD+
- Claim 22: PFS about 15 to 25 months greater when HRD+ with BRCA mutation
Claim 23 is an alternative hypertension guardrail:
- olaparib prevents developing CTCAE Grade 2–4 hypertension.
How broad is US 11,970,530’s claim scope: method-of-use, dosing, and biomarker gating?
Breadth on indication: moderate to broad
The claim covers multiple solid tumors (ovarian/fallopian/primary peritoneal, breast, pancreatic). In US practice, this matters for enforcement because defendants often argue that the evidentiary basis and clinical context in the specification is narrow. Still, the claim language itself is broad on cancer types.
Breadth on regimen: relatively narrow by dose and schedule
- bevacizumab fixed range: 10–20 mg/kg Q3W
- olaparib fixed: 300 mg BID
Any generic or biosimilar pathway aiming to avoid infringement would focus first on dose/schedule and olaparib regimen equivalence (hydrate/solvate/prodrug scope is explicitly captured). If a product uses olaparib 300 mg BID and bevacizumab within 10–20 mg/kg Q3W, the “dose gate” does not help.
Breadth on biomarkers and patient selection: layered narrowings
The dependent claims create multiple “fences” that can be asserted selectively:
- HRD designation (Claim 3)
- HR gene list (Claim 4)
- BRCA/ATM combinations (Claims 5–6)
- tBRCA (Claim 7)
- gBRCA and epithelial subsets (Claims 10–11)
From a litigation posture perspective, this enables plaintiffs to select the best-supported subgroup for infringement and damages.
Breadth on outcome metrics: hardest-to-replicate features
The comparative elements:
- reduction in CTCAE Grade 2–4 hypertension vs bevacizumab alone
- PFS differential thresholds vs bevacizumab alone (≥4 months, and higher thresholds in dependent claims)
These are frequently the points where defendants will dispute:
- measurement approach
- CTCAE adjudication timing
- comparability of control arms
- whether “bevacizumab alone” is truly the comparator used clinically
- whether the claimed patient populations are congruent
But the claim is still enforceable if a real-world or trial-based practice aligns.
What patents are likely combined with or adjacent to US 11,970,530 for bevacizumab-olaparib regimens in the US?
Adjacency categories that define the landscape
Even without enumerating every co-pending US family member here, a complete FTO and portfolio view for this combination will almost always be populated by these US patent buckets:
-
Olaparib composition/salt/formulation patents
Typically earlier and numerous, often spanning hydrates/solvates/prodrugs.
-
Bevacizumab administration method patents
Usually older and broad, sometimes focusing on dosing schedules.
-
Combination therapy method-of-treatment patents
Often filed around:
- patient selection (HRD, BRCA, gBRCA/tBRCA)
- prior therapy settings (post first-line platinum/taxane; interval before olaparib)
- regimen pairing (bevacizumab with PARP inhibitor)
-
Dose and schedule-specific patents
Claiming Q3W bevacizumab dose bands and fixed olaparib dosing.
-
Biomarker and stratification patents
Enabling “HRD+” and gene mutation subsets to be protected.
-
Safety-discriminator patents
Claims that tie PFS benefit to tolerability metrics such as CTCAE hypertension.
-
Regulatory exclusivity vs patent exclusivity
Different from patents, but it drives generic entry timing strategy and Paragraph IV decisions.
Where 11,970,530 sits within that architecture
US 11,970,530’s standout feature is that it bundles:
- a fixed regimen (bevacizumab range + olaparib 300 mg BID)
- a biomarker gate (HRD and gene lists in dependents)
- and a comparative clinical-outcome gate (CTCAE hypertension differential and PFS differential vs bevacizumab alone)
That configuration is a common “late-portfolio” strategy: it is meant to persist after earlier broad combination claims, by claiming specific patient groups and measured outcomes.
When does exclusivity end for bevacizumab + olaparib, and how do patents like 11,970,530 affect generic or biosimilar entry?
Practical timeline mechanics for US entry
For US generics and biosimilars, entry risk is driven by two parallel tracks:
- Patent term expiration (utility patents; terminal disclaimers; PTA extensions)
- Regulatory exclusivity (often separate; but you asked specifically about the patent scope, so this focuses on how 11,970,530 functions in litigation)
How 11,970,530 blocks entry
If a generic/biosimilar intends to launch a PARP inhibitor and use it in the claimed combination regimen, infringement risk exists even if:
- the launch uses an approved label that differs slightly, because method claims can reach off-label or label-adjacent clinical practice if the claim elements are satisfied.
The claim’s built-in “versus bevacizumab alone” comparator does not eliminate infringement risk. It shifts the question to whether the clinical dataset or practice establishes the comparative outcomes threshold. Trials or real-world studies in litigation typically become the evidence.
What Paragraph IV or non-infringement strategies would target US 11,970,530’s claim features?
Strategy cluster A: dosing and regimen avoidance
Because Claim 1 is dose bounded, a common defendant approach is:
- avoid bevacizumab within 10–20 mg/kg Q3W, or
- avoid olaparib 300 mg BID, or
- avoid an administration pattern that maps to the dependent cycle limits (e.g., no more than 22 cycles).
Strategy cluster B: patient selection and biomarker gates
Defendants can narrow alleged infringement by showing:
- the patient population in practice is not HRD or does not map to the defined mutation set
- the trial population is not enriched for BRCA/ATM mutations as required by the dependents
Strategy cluster C: outcome-based non-infringement
The “hard fence” for defendants is disputing that the combination produces:
- the claimed CTCAE hypertension differential versus bevacizumab alone
- the claimed PFS differential magnitude (≥4 months in Claim 1; higher thresholds in Claims 20–22)
In infringement disputes, these are evidence-intensive. Plaintiffs may rely on the underlying clinical program supporting the combination and specific statistical cutoffs, while defendants attack comparability and measurement definitions.
How strong is US 11,970,530’s enforceability profile based on its claim structure?
Strong points (from a claimant’s view)
- The claim is specific, reducing prior-art overlap for broad “combination therapy” patents.
- It has clear dosing anchors (bevacizumab mg/kg and Q3W; olaparib 300 mg BID).
- It includes biomarker and histology subsets, enabling targeted enforcement in likely high-value clinical segments (HRD+/BRCA).
- It adds clinical outcome discriminators that can be difficult for defendants to match using alternative regimen variations.
Weak points (from a defendant’s view)
- Comparative-outcome claims can be attacked via differences in comparator arm and statistical interpretation.
- If the specification’s support does not line up with the full breadth (multiple tumor types plus wide mutation list), defendants may seek to narrow claim construction.
- CTCAE grading is adjudicator- and trial-design dependent; disputes may arise on what constitutes “as compared to bevacizumab alone.”
What does the biomarker language (HRD+, BRCA1/2, ATM, gBRCA/tBRCA) imply for infringement and licensing?
HRD+ and gene lists create sublicenseable subpopulations
From a commercial perspective, the claims align with high-value diagnostics-driven markets:
- HRD testing to identify HRD+ status
- BRCA1/2 germline or tumor mutation stratification
- ATM and broader HR gene inclusion
Licensing in this space typically leverages:
- a defined diagnostic algorithm
- defined prior therapy cohorts (post first-line platinum/taxane, and bevacizumab exposure)
- a treatment duration structure (cycle caps)
This makes the claims “implementable,” which is favorable for enforcement and for license scope definition.
Comparative landscape: how US 11,970,530 differs from earlier bevacizumab + PARP inhibitor patents (typical patterns)
Earlier patents often cover broader combination use without outcome-comparative thresholds
Many earlier method patents focus on:
- combination for cancer treatment
- HRD/BRCA stratification
- general dosing ranges
US 11,970,530’s differentiator is the explicit inclusion of:
- CTCAE hypertension differential vs bevacizumab alone
- PFS improvement magnitude vs bevacizumab alone
- explicit bevacizumab mg/kg banding every 3 weeks and fixed olaparib dosing
That makes it harder to design around by “same combination, different trial” unless you can truly avoid the dose/schedule or patient selection.
Key takeaways
- US 11,970,530 Claim 1 is a tightly engineered combination regimen claim for bevacizumab (10–20 mg/kg Q3W) + olaparib (300 mg BID) across specified cancers, with comparative outcome fences: reduced CTCAE Grade 2–4 hypertension and increased PFS versus bevacizumab alone.
- Dependent claims layer enforceable gates: HRD status; HR gene mutation list; BRCA1/2 and ATM variants; epithelial histology; prior first-line platinum/taxane cycles; timing window before olaparib; bevacizumab cycle cap; hypertension identification/grade; and higher PFS differentials in BRCA/HRD+ subgroups.
- Design-around levers are narrow but real: move outside the bevacizumab dose band or Q3W schedule, avoid olaparib 300 mg BID, avoid HRD/BRCA-defined populations, or avoid treatment contexts that align with the claimed comparative endpoints.
- For licensing and litigation strategy, the claim’s comparative clinical-outcome construction is the primary strength and primary evidence battleground.
FAQs
-
Does US 11,970,530 cover olaparib hydrates/solvates/prodrugs?
Yes. Claim 1 expressly includes olaparib and a hydrate/solvate/prodrug thereof.
-
What patient subgrouping is required in the strongest dependent claims?
HRD status and specific HR gene mutations, with additional BRCA1/2 and ATM variants in dependents, plus gBRCA/tBRCA constructs in Claims 7 and 10.
-
Is bevacizumab dose timing material to infringement?
Yes. Claim 1 requires bevacizumab 10–20 mg/kg every 3 weeks, and dependents further specify ~15 mg/kg Q3W.
-
How can CTCAE hypertension language be used in enforcement?
It provides a comparative tolerability fence: the combination must reduce CTCAE Grade 2–4 hypertension versus bevacizumab alone.
-
What efficacy threshold is built into the independent claim?
PFS must be at least about 4 months greater versus bevacizumab alone, with larger required differentials in dependent claims for BRCA and HRD+ subsets.
References
- Provided claim text for US Patent 11,970,530 (user-provided).
